Skip to content
value.today

Accelerate Diagnostics, Inc.: financial analysis

Ratios worked out from 10 fiscal years of Accelerate Diagnostics, Inc.'s statements, compared with 87 companies in Diagnostics and Research.

Operating margin, 2024
-301.8%
Diagnostics and Research: -2.4%
Revenue growth, 3 years a year, 2024
-0.2%
Diagnostics and Research: 3.6%
Free cash flow margin, 2024
-211.1%
Diagnostics and Research: 4.7%

Accelerate Diagnostics, Inc. scorecard#

Passes 2 of the 13 checks that could be worked out: strongest in profitability (1 of 4), weakest in growth (1 of 6). Fiscal year 2024.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-3.0%Revenue down 3.0% in fiscal 2024.
    • ✗Revenue up more than 5% a year over three years-0.2%-0.2% a year over the three years to fiscal 2024.
    • ✗Faster growth over three years than its peers' median-0.2%-0.2% a year against Diagnostics and Research's median of 3.6% (64 companies).
    • ✗Earnings per share grew in the newest year-2.15 vs -4.94Diluted EPS -2.15 in fiscal 2024 against -4.94 the year before (report's currency).
    • ✓Net income higher than five years earlier-$50 M-$50 M in fiscal 2024 against -$84 M in 2019.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2024.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$50 MNet income -$50 M in fiscal 2024.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2024.
    • ✗Operating margin above its peers' median-301.8%-301.8% against Diagnostics and Research's median of -2.4% (66 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-301.8%-301.8% in fiscal 2024 against -607.5% in 2021.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.7×Current ratio 0.71 at the end of fiscal 2024.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year86.8%Diluted shares up 86.8% in fiscal 2024.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2024 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Worth a look

  • Revenue fell 3.0% against the year before.
  • Net loss of $50 million, the 14th loss-making year in a row.
  • Free cash flow was negative: -$25 million.
  • The share count rose 86.8% in the year.
  • Shareholders' equity is negative: -$56 million.
  • Liabilities due within a year exceed current assets (current ratio 0.71).

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

4of 8(1 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profitno
  • Operations brought in cashno
  • Return on assets roseyes
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsnot on file
  • Current ratio roseno
  • No new shares issuedno
  • Gross margin roseyes
  • Asset turnover roseyes

Profitability#

Accelerate Diagnostics, Inc.: profitability by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Gross margin23.1%21.1%25.9%-3.2%40.0%55.7%12%
Operating margin-301.8%-448.0%-492.6%-607.5%-570.8%-2.4%8%
Net margin-427.7%-511.0%-490.1%-659.6%-700.8%-3.6%1%
Return on equity—————-5.4%—
Return on assets-167.0%-127.9%-84.4%-88.1%-68.7%-7.1%7%

Growth#

Accelerate Diagnostics, Inc.: growth by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Revenue growth-3.0%-5.4%8.2%5.6%20.0%6.6%17%
Revenue growth, 3 years a year-0.2%2.6%11.1%27.6%38.7%3.6%33%
Revenue growth, 5 years a year4.7%16.3%25.0%116.1%136.8%9.7%28%

Financial strength#

Accelerate Diagnostics, Inc.: financial strength by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Debt to equity—————0.57×—
Net debt———$-40 M$-31 M$270 M—
Interest cover——-27.67×-4.60×-4.10×-3.31×—
Current ratio0.71×2.03×0.84×10.57×11.76×1.97×12%
Equity share of assets-196.2%-63.4%-34.2%-42.2%-67.3%51.8%1%

Cash#

Accelerate Diagnostics, Inc.: cash by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Free cash flow$-25 M$-41 M$-49 M$-48 M$-52 M$-2 M21%
Free cash flow margin-211.1%-342.0%-386.5%-406.8%-463.7%4.7%5%
Capital spending share of revenue4.4%8.6%4.3%5.1%12.2%3.3%—

Shareholder returns#

Accelerate Diagnostics, Inc.: shareholder returns by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Change in share count86.8%51.9%33.1%-89.0%2.8%2.8%13%

Efficiency#

Accelerate Diagnostics, Inc.: efficiency by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Asset turnover0.39×0.25×0.17×0.13×0.10×0.63×28%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Capital spending share of revenue
Capital spending as a share of revenue.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Accelerate Diagnostics, Inc.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 87 companies in Diagnostics and Research that Accelerate Diagnostics, Inc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Accelerate Diagnostics, Inc.